Ardelyx has entered into pharma licensing with Sanofi for its novel phosphate transport NaP2b inhibitor program (also known as NaPi2b, Npt2b and SLC34A2) for $198 million.
Ardelyx will receive an undisclosed upfront payment from Sanofi.
Total development and regulatory milestones could potentially reach up to $198 million.
Ardelyx would also be entitled to royalties on product sales.
Ardelyx retains an option to participate in co-promotional activities for the US market.
Ardelyx's NaP2b program includes a portfolio of minimally-absorbed NaP2b inhibitors in discovery and preclinical stage of development.
Sanofi will have full responsibility for further discovery efforts and development of any products.
NaP2b is an intestinal phosphate transporter whose activity accounts for a significant portion of dietary phosphate absorption in humans.
The inhibition of NaP2b should have utility for the treatment of hyperphosphatemia (elevated serum phosphate) in patients with end stage renal disease (ESRD) and other forms of chronic kidney disease (CKD).
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Practical Guide to Finding Partners
Report: Partnering Deals and Alliances with Sanofi
Related reports: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity